Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid

[11] Leer JW(2012)Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials Eur J Cancer 48 3082-3092

[12] Cleeland CS(1996)Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling Pain 67 267-273

[13] Gonin R(1993)The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 570-579

[14] Hatfield AK(2011)Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form J Support Oncol 9 72-78

[15] Edmonson JH(2000)Defining the clinically important difference in pain outcome measures Pain 88 287-294

[16] Blum RH(2003)The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation Health Qual Life Outcomes 1 79-6235s

[17] Stewart JA(2006)Biology of bone cancer pain Clin Cancer Res 12 6231s-105

[18] Pandya KJ(2011)Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain Bone 48 100-528

[19] Deandrea S(2000)Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord Nat Med 6 521-287

[20] Montanari M(2011)Expert conference on cancer pain assessment and classification—the need for international consensus: working proposals on international standards BMJ Support Palliat Care 1 281-1115

[11] Leer JW(2012)Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials Eur J Cancer 48 3082-3092

[12] Cleeland CS(1996)Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling Pain 67 267-273

[13] Gonin R(1993)The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 570-579

[14] Hatfield AK(2011)Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form J Support Oncol 9 72-78

[15] Edmonson JH(2000)Defining the clinically important difference in pain outcome measures Pain 88 287-294

[16] Blum RH(2003)The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation Health Qual Life Outcomes 1 79-6235s

[17] Stewart JA(2006)Biology of bone cancer pain Clin Cancer Res 12 6231s-105

[18] Pandya KJ(2011)Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain Bone 48 100-528

[19] Deandrea S(2000)Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord Nat Med 6 521-287

[20] Montanari M(2011)Expert conference on cancer pain assessment and classification—the need for international consensus: working proposals on international standards BMJ Support Palliat Care 1 281-1115